---
layout: default
title: Dupilumab
description: "Dupilumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 64
evidence_level: L1
indication_count: 10
---

# Dupilumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Dupilumabï¼šå¾ç•°ä½æ€§çš®è†šç‚åˆ°æ”¯æ°£ç®¡ç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Dupilumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Dupilumab åŸæœ¬ç”¨æ–¼æ²»ç™‚ä¸­è‡³é‡åº¦ç•°ä½æ€§çš®è†šç‚ã€æ°£å–˜åŠæ…¢æ€§é¼»ç«‡ç‚åˆä½µé¼»æ¯è‚‰ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ”¯æ°£ç®¡ç‚ (bronchitis)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **1 å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç•°ä½æ€§çš®è†šç‚ã€æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚åˆä½µé¼»æ¯è‚‰ã€å—œä¼Šç´…æ€§é£Ÿé“ç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bronchitisã€çš®è†šç‚ã€acne keloidã€exanthem (disease)ã€neonatal dermatomyositisã€acrodermatitis chronica atrophicansã€amyopathic dermatomyositisã€secondary interstitial lung disease specific to childhood associated with a connective tissue diseaseã€hydroa vacciniforme, familialã€atopic eczema |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.92% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. bronchitis</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.92%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Dupilumab æ˜¯ä¸€ç¨®äººæºåŒ–å–®æ ªæŠ—é«”ï¼Œå¯é˜»æ–· IL-4 å’Œ IL-13 çš„è¨Šè™Ÿå‚³éï¼Œ</p>
<p>é€™å…©ç¨®ç´°èƒå› å­æ˜¯ç¬¬äºŒå‹ç™¼ç‚åæ‡‰çš„é—œéµä»‹è³ªã€‚æ”¯æ°£ç®¡ç‚ï¼Œç‰¹åˆ¥æ˜¯å—œé…¸æ€§æ”¯æ°£ç®¡ç‚ï¼Œ</p>
<p>æ¶‰åŠé¡ä¼¼çš„ç™¼ç‚æ©Ÿè½‰ã€‚Dupilumab å·²æ ¸å‡†ç”¨æ–¼å—œé…¸æ€§ç™½è¡€çƒè¡¨ç¾å‹çš„æ°£å–˜ï¼Œ</p>
<p>å…¶å°ä¸‹å‘¼å¸é“ç™¼ç‚çš„æŠ‘åˆ¶ä½œç”¨å¯èƒ½å»¶ä¼¸è‡³æ”¯æ°£ç®¡ç‚çš„æ²»ç™‚ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT04362501">NCT04362501</a></td>
<td>Phase 2</td>
<td>COMPLETED</td>
<td>33</td>
<td>è©•ä¼° dupilumab åœ¨ç„¡é¼»æ¯è‚‰çš„æ…¢æ€§é¼»ç«‡ç‚æ‚£è€…çš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03346434">NCT03346434</a></td>
<td>Phase 2/3</td>
<td>COMPLETED</td>
<td>202</td>
<td>è©•ä¼° dupilumab åœ¨ 6 å€‹æœˆè‡³ 6 æ­²ç•°ä½æ€§çš®è†šç‚å…’ç«¥çš„è—¥å‹•å­¸å’Œç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01949311">NCT01949311</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>2733</td>
<td>Dupilumab åœ¨ç•°ä½æ€§çš®è†šç‚æˆäººæ‚£è€…çš„é•·æœŸå®‰å…¨æ€§ç ”ç©¶</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT04287621">NCT04287621</a></td>
<td>N/A</td>
<td>ACTIVE_NOT_RECRUITING</td>
<td>718</td>
<td>RAPID ç™»è¨˜ç ”ç©¶ï¼šæ°£å–˜æ‚£è€…ä½¿ç”¨ dupilumab çš„çœŸå¯¦ä¸–ç•Œæ•¸æ“š</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT02277769">NCT02277769</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>708</td>
<td>ç¢ºèª dupilumab å–®è—¥æ²»ç™‚ä¸­è‡³é‡åº¦ç•°ä½æ€§çš®è†šç‚çš„ç™‚æ•ˆ</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34597534/">34597534</a></td>
<td>2022</td>
<td>RCT extension</td>
<td>Lancet Respir Med</td>
<td>TRAVERSE ç ”ç©¶ï¼šdupilumab åœ¨ä¸­è‡³é‡åº¦æ°£å–˜çš„é•·æœŸå®‰å…¨æ€§å’Œç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30273510/">30273510</a></td>
<td>2019</td>
<td>Meta-analysis</td>
<td>J Asthma</td>
<td>Dupilumab åœ¨æ§åˆ¶ä¸ä½³æ°£å–˜çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ç³»çµ±æ€§å›é¡§</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/38488768/">38488768</a></td>
<td>2024</td>
<td>Case report</td>
<td>Pediatr Pulmonol</td>
<td>Dupilumab ç”¨æ–¼å…’ç«¥å—œé…¸æ€§å¡‘å‹æ€§æ”¯æ°£ç®¡ç‚çš„æ–°ç™‚æ³•</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30196731/">30196731</a></td>
<td>2018</td>
<td>Review</td>
<td>Expert Opin Pharmacother</td>
<td>å¸è¸ç›¸é—œæ°£é“ç–¾ç—…åˆä½µæ°£å–˜çš„æ²»ç™‚æŒ‘æˆ°</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/32428511/">32428511</a></td>
<td>2020</td>
<td>Clinical study</td>
<td>Chest</td>
<td>æŠ— T2 ç”Ÿç‰©è£½åŠ‘æ²»ç™‚å°é¡å›ºé†‡ä¾è³´å‹æ°£å–˜è‚ºé€šæ°£çš„å½±éŸ¿</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. dermatitis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03884842" target="_blank">NCT03884842</a></td><td>PHASE3</td><td>COMPLETED</td><td>24</td><td>A Two-arm, Placebo-controlled Randomized Clinical Trial to Evaluate the Effect o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03346434" target="_blank">NCT03346434</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>202</td><td>A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Du...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05268107" target="_blank">NCT05268107</a></td><td>PHASE4</td><td>RECRUITING</td><td>30</td><td>Ethnic Differences in Mechanisms of Action of Dupilumab</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04183335" target="_blank">NCT04183335</a></td><td>PHASE3</td><td>COMPLETED</td><td>151</td><td>A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Stu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05527964" target="_blank">NCT05527964</a></td><td>N/A</td><td>COMPLETED</td><td>146</td><td>The Influence of Specific Targeted Therapy on Subject and Family Quality of Life...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36214355/" target="_blank">36214355</a></td><td>2022</td><td>Article</td><td>Journal of cutaneous</td><td>Treatment With Dupilumab in Patients With Atopic Dermatitis:...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30194992/" target="_blank">30194992</a></td><td>2019</td><td>Article</td><td>The Journal of aller</td><td>Dupilumab progressively improves systemic and cutaneous abno...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34126094/" target="_blank">34126094</a></td><td>2022</td><td>Article</td><td>Journal of the Ameri</td><td>Management of inadequate response and adverse effects to dup...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38560522/" target="_blank">38560522</a></td><td>2024</td><td>Article</td><td>Drug design, develop</td><td>A Review of Dupilumab in the Treatment of Atopic Dermatitis ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39588375/" target="_blank">39588375</a></td><td>2024</td><td>Article</td><td>Frontiers in immunol</td><td>Immunogenicity of dupilumab in adult and pediatric patients ...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. acne keloid</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.61%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37360650/" target="_blank">37360650</a></td><td>2023</td><td>Article</td><td>JAAD case reports</td><td>Effects of dupilumab on keloid stabilization and prevention.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. exanthem (disease)</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ10 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04447417" target="_blank">NCT04447417</a></td><td>PHASE4</td><td>COMPLETED</td><td>52</td><td>Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06012448" target="_blank">NCT06012448</a></td><td>PHASE4</td><td>COMPLETED</td><td>10</td><td>The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04718870" target="_blank">NCT04718870</a></td><td>PHASE4</td><td>COMPLETED</td><td>41</td><td>Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05394792" target="_blank">NCT05394792</a></td><td>N/A</td><td>COMPLETED</td><td>111</td><td>CANadian Effectiveness of UPadacitinib in Adult Moderate-to-severe aTopIc derMat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07352566" target="_blank">NCT07352566</a></td><td>PHASE4</td><td>NOT_YET_RECRUITING</td><td>10</td><td>Utilization of a Cutaneous Therapy In Situ Microdevice</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 5 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ11 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40375468/" target="_blank">40375468</a></td><td>2025</td><td>Article</td><td>International journa</td><td>Dupilumab for the Treatment of Cutaneous Immune-Related Adve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33207021/" target="_blank">33207021</a></td><td>2021</td><td>Article</td><td>Clinical and experim</td><td>Skin manifestations of COVID-19 in children: Part 3.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40507326/" target="_blank">40507326</a></td><td>2025</td><td>Article</td><td>Cancers</td><td>Interleukin-4 and -13 Gene Expression Profiles in Immune-Rel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38008067/" target="_blank">38008067</a></td><td>2023</td><td>Article</td><td>Respiration; interna</td><td>Adverse Effects Under Th2 Biologics (Dupilumab and Tezepelum...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37203799/" target="_blank">37203799</a></td><td>2023</td><td>Article</td><td>International journa</td><td>Detection of novel therapies using a multi-national, multi-i...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 6 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. neonatal dermatomyositis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.56%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. acrodermatitis chronica atrophicans</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.54%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. amyopathic dermatomyositis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. secondary interstitial lung disease specific to childhood associated with a connective tissue disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.52%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. hydroa vacciniforme, familial</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.50%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. severe nonproliferative diabetic retinopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.10%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| 2 å¼µè¨±å¯è­‰ | æœé¿ç‚æ³¨å°„åŠ‘300æ¯«å…‹ | æ³¨å°„åŠ‘ | ç•°ä½æ€§çš®è†šç‚ã€æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚åˆä½µé¼»æ¯è‚‰ã€å—œä¼Šç´…æ€§é£Ÿé“ç‚ã€COPDã€æ…¢æ€§è‡ªç™¼æ€§è•éº»ç–¹ |

## å®‰å…¨æ€§è€ƒé‡

- **å¸¸è¦‹ä¸è‰¯åæ‡‰**ï¼šæ³¨å°„éƒ¨ä½åæ‡‰ã€çµè†œç‚ã€å£å”‡çš°ç–¹
- **é‡è¦æ³¨æ„äº‹é …**ï¼šé–‹å§‹æ²»ç™‚å‰æ‡‰è©•ä¼°å¯„ç”ŸèŸ²æ„ŸæŸ“ï¼Œä¸å»ºè­°èˆ‡æ´»ç—…æ¯’ç–«è‹—åŒæ™‚ä½¿ç”¨
- **ç‰¹æ®Šæ—ç¾¤**ï¼šå…’ç«¥ä½¿ç”¨éœ€æŒ‰é«”é‡èª¿æ•´åŠ‘é‡


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Helminthiasis** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Vision Disorders** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Dupilumab æŠ‘åˆ¶ IL-4/IL-13 çš„æ©Ÿè½‰é©ç”¨æ–¼å—œé…¸æ€§ç™¼ç‚ç›¸é—œçš„æ”¯æ°£ç®¡ç‚ï¼Œ
å·²æœ‰ç—…ä¾‹å ±å‘Šæ”¯æŒå…¶åœ¨å—œé…¸æ€§å¡‘å‹æ€§æ”¯æ°£ç®¡ç‚çš„ç™‚æ•ˆã€‚éœ€å€åˆ†æ”¯æ°£ç®¡ç‚çš„äºå‹ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å€åˆ†å—œé…¸æ€§èˆ‡éå—œé…¸æ€§æ”¯æ°£ç®¡ç‚çš„ç”Ÿç‰©æ¨™è¨˜
- é‡å°æ…¢æ€§æ”¯æ°£ç®¡ç‚æ‚£è€…çš„å‰ç»æ€§è‡¨åºŠè©¦é©—
- èˆ‡ COPD åˆä½µå—œé…¸æ€§ç™½è¡€çƒå¢é«˜æ‚£è€…çš„æ²»ç™‚æ•ˆç›Šè©•ä¼°

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dorzolamide]({{ "/drugs/dorzolamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Dupilumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/dupilumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_dupilumab,
  title = {Dupilumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/dupilumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
